106 related articles for article (PubMed ID: 7908818)
21. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
McKelvie PA; Chan F; Yu Y; Waring P; Gresshoff I; Farrell S; Williams RA
Pathology; 2013 Dec; 45(7):637-44. PubMed ID: 24247620
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
23. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population.
Mishra A; Agrawal V; Krishnani N; Mishra SK
J Postgrad Med; 2009; 55(3):171-5. PubMed ID: 19884740
[TBL] [Abstract][Full Text] [Related]
25. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
[TBL] [Abstract][Full Text] [Related]
26. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
27. Oncogene amplification and overexpression of oncoproteins in thyroid papillary cancer.
Várkondi E; Gyory F; Nagy A; Kiss I; Ember I; Kozma L
In Vivo; 2005; 19(2):465-70. PubMed ID: 15796211
[TBL] [Abstract][Full Text] [Related]
28. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
29. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
30. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
31. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
32. Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma.
Brzeziński J; Migodziński A; Toczek A; Tazbir J; Dedecjus M
Clin Cancer Res; 2005 Feb; 11(3):1037-43. PubMed ID: 15709169
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
34. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
[TBL] [Abstract][Full Text] [Related]
35. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
36. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
[TBL] [Abstract][Full Text] [Related]
38. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma.
Li WF; Wang G; Zhao ZB; Liu CA
Clin Endocrinol (Oxf); 2015 Oct; 83(4):572-80. PubMed ID: 25418110
[TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
40. Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma.
Omura K; Nagasato A; Kanehira E; Kinsen H; Amaya S; Kimura K; Kajita T; Nozaki Y; Mizukami Y; Nonomura A; Watanabe Y
J Clin Oncol; 1997 Dec; 15(12):3458-63. PubMed ID: 9396398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]